- Home
- EBS vs MAZE Comparison
EBS vs MAZE Comparison
Compare EBS & MAZE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- MAZE
- Stock Information
- Founded
- EBS 1998
- MAZE 2018
- Country
- EBS United States
- MAZE United States
- Employees
- EBS N/A
- MAZE N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- MAZE
- Sector
- EBS Health Care
- MAZE
- Exchange
- EBS Nasdaq
- MAZE NYSE
- Market Cap
- EBS 393.9M
- MAZE 367.0M
- IPO Year
- EBS 2006
- MAZE 2025
- Fundamental
- Price
- EBS $6.34
- MAZE $13.87
- Analyst Decision
- EBS Strong Buy
- MAZE Strong Buy
- Analyst Count
- EBS 3
- MAZE 3
- Target Price
- EBS $14.33
- MAZE $25.67
- AVG Volume (30 Days)
- EBS 1.4M
- MAZE 103.6K
- Earning Date
- EBS 05-07-2025
- MAZE 05-14-2025
- Dividend Yield
- EBS N/A
- MAZE N/A
- EPS Growth
- EBS N/A
- MAZE N/A
- EPS
- EBS N/A
- MAZE 0.34
- Revenue
- EBS $965,400,000.00
- MAZE $167,500,000.00
- Revenue This Year
- EBS N/A
- MAZE N/A
- Revenue Next Year
- EBS $16.07
- MAZE N/A
- P/E Ratio
- EBS N/A
- MAZE $41.23
- Revenue Growth
- EBS N/A
- MAZE N/A
- 52 Week Low
- EBS $4.02
- MAZE $6.71
- 52 Week High
- EBS $15.10
- MAZE $17.00
- Technical
- Relative Strength Index (RSI)
- EBS 55.56
- MAZE N/A
- Support Level
- EBS $6.20
- MAZE N/A
- Resistance Level
- EBS $6.68
- MAZE N/A
- Average True Range (ATR)
- EBS 0.38
- MAZE 0.00
- MACD
- EBS -0.03
- MAZE 0.00
- Stochastic Oscillator
- EBS 59.94
- MAZE 0.00
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About MAZE MAZE THERAPEUTICS INC
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.